BIOAFFINITY TECHNOLOGIES INC

BioAffinity Technologies turns cancer care into a non‑invasive, precise revolution—early detection and targeted therapies that cut risk, cost, and harm.

bioAffinity Technologies files a 1-for-15 reverse stock split to meet Nasdaq’s bid‑price rule, preserving its listing while offering cash for fractional shares.

Discover how bioAffinity Technologies Inc. is pioneering non‑invasive lung cancer diagnostics, especially for veterans, with its CyPath® Lung test and upcoming webinar.

bioAffinity Technologies Inc. pioneers non‑invasive cancer diagnostics and therapeutics—discover its biotech innovations, stock trends, and future potential.

bioAffinity Technologies Inc. pioneers non‑invasive cancer diagnostics and therapeutics, turning promise into profit‑potential while navigating biotech volatility.